Mineralys Therapeutics (MLYS) Net Cash Flow (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Net Cash Flow data on file, last reported at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 218.12% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$52.2 million (down 170.02% YoY), and the FY2025 full-year result was $58.8 million, down 9.19% from the prior year.
• Net Cash Flow eased to -$60.1 million in Q1 2026, from -$44.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $115.9 million in Q3 2025 to a low of -$79.3 million in Q3 2022.
• A 5-year average of $6.0 million and a median of $5.4 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 832.74% in 2023 and slumped 365.83% in 2025, its largest moves.
• Tracing MLYS's Net Cash Flow over 5 years: stood at $38.7 million in 2022, then slumped by 195.48% to -$37.0 million in 2023, then surged by 145.46% to $16.8 million in 2024, then tumbled by 365.83% to -$44.7 million in 2025, then sank by 34.53% to -$60.1 million in 2026.
• Business Quant data shows MLYS's Net Cash Flow at -$60.1 million in Q1 2026, -$44.7 million in Q4 2025, and $115.9 million in Q3 2025.